ALRN News and Press, Aileron Therapeutics Inc. From 04/21/22

Mr. Zergebel brings over 20 years of industry experience, primarily focused in oncology, and broad expertise to help Aileron ensure operational excellence Aileron is advancing ALRN-6924 with the goal of delivering a chemoprotective agent for patients with p53-mutated cancer Clinic...

Aileron Therapeutics Inc. (NASDAQ:ALRN) traded today at a new 52-week high of $15.33. So far today approximately 65.8 million shares have been exchanged, as compared to an average 30-day volume of 448,000 shares. Aileron Therapeutics Inc. (NASDAQ:ALRN) defies analysts with a current pric...

Aileron Therapeutics press release (NASDAQ:ALRN): Q4 GAAP EPS of -$0.08 in-line. As of December 31, 2021, cash, cash equivalents and investments were $45.9 million, compared to $13.8 million as of December 31, 2020. The company expects, based on its current operating plan, that its existing c...

Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or chemotherapy Expected readouts for Phase 1b trial in p53-mutated non-small cell lun...

3 Penny Stocks to Add to Your Watchlist in April There is no simple answer to the question of whether penny stocks are a good investment or not. It depends on a variety of factors, including the current state of the economy, the company’s financial stability, and your own persona...

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., Pr...

Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22 Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track for interim results in 2Q22 and t...

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive O...

BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a member of the company's Scientific Advisory Board since 2011. “We are deeply s...

Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned NSCLC study data readouts include interim results in 2Q22; topline full results in 4Q2...